General Surgery Coding Alert - 2006 Issue 29
PHARMACEUTICALS: Part D Paying Off For Big Pharma
Subscribe or sign in to view the full article.
Article Overview
This article covers how Medicare Part D was affecting pharmaceutical company earnings and prescription sales in its early rollout period. It focuses on broad industry impact, prescription volume, and analyst commentary about companies benefiting from coverage changes for Medicare beneficiaries, especially dual eligibles. The piece is relevant to readers tracking drug benefit policy, payer coverage trends, and pharmaceutical market effects.
Why This Topic Matters
It helps readers understand the early market response to Medicare Part D and how coverage changes can influence prescription volume and company revenue trends.
What You Will Learn
- How Medicare Part D was affecting pharmaceutical sales in the early coverage period.
- What prescription volume trends were being reported for the new drug benefit.
- How analysts were estimating financial effects on selected drug manufacturers.
- How coverage changes for Medicare beneficiaries were influencing broader market performance.
Who Should Read This
- Health policy analysts
- Medical coders and billing professionals
- Payer and reimbursement analysts
- Pharmaceutical industry analysts
- Healthcare market researchers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com